ALB and neoplasm: A wide range of covariates were assessed, including body weight, race, tumor type, age, sex, creatinine clearance (37.1 to 272.2 ml/min), albumin, mild hepatic impairment (by the definition of the National Cancer Institute), ECOG performance status, and antidrug antibodies, and were found to have no clinically important effects on the PK of sintilimab.